NOXXON Pharma AG Achieves Milestone in Partnership with Eli Lilly and Company
07-Dec-2009
- Germany
Following the completion of the discovery work, the identified Spiegelmer® will undergo pharmacological testing and pre-clinical development. Lilly is responsible for the pre-clinical and clinical development as well as the commercialization of the Spiegelmer® product, provided the product is approved by regulatory authorities.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.